Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...

Data Presented at European Association of Urology Highlights Safety and Versatility of the Minimally Invasive UroLift System in a Real-World Setting WAYNE, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- ...

Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) - Additional studies examine ...

WAYNE, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of positive results from a multi-center study reaffirming the safety and effectiveness ...

WAYNE, Pa., May 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a leading global provider of medical technologies, today announced the full U.S. commercial launch of its UroLift ® 2 System ...

BPH is a non-cancerous enlargement of the prostate, occurring naturally as men age, which can cause urinary problems, decrease quality of life, and interrupt sleep. 4 More than 14 million men in the U ...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) today announced that 100,000 patients have been treated globally with its minimally invasive UroLift ® System, a safe and effective ...

WAYNE, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the presentation of new clinical data at the American Urological Association (AUA) 2019 Annual Meeting ...